CD200R1

CD200R1, also named CD200 receptor 1, is a cell-surface receptor of the immunoglobulin superfamily that binds the ligand CD200. It forms part of the CD200-CD200R axis, a signaling pathway that helps regulate immune activation and maintain tissue homeostasis. CD200R1 is primarily inhibitory, acting to dampen inflammatory responses when engaged by CD200.

Expression and signaling are context dependent. CD200R1 is most prominently expressed on cells of the myeloid lineage, such as macrophages and dendritic cells, with additional expression on some lymphocytes in humans. Upon binding CD200, CD200R1 transduces inhibitory signals that limit cellular activation. The receptor contains cytoplasmic motifs that recruit phosphatases through adaptor molecules, leading to downregulation of pro-inflammatory pathways and reduced cytokine production and phagocytic activity.

Function and physiological role are centered on maintaining self-tolerance and preventing excessive tissue damage during immune responses. The CD200-CD200R1 axis contributes to immune regulation in various tissues, including the nervous system and retina, and modulates responses during infection and injury. It also plays a role in preventing excessive activation of microglia and other resident immune cells in sensitive environments.

Clinical relevance is observed in several disease contexts. Abnormal CD200R1 signaling has been implicated in autoimmune and neuroinflammatory conditions, where insufficient inhibitory signaling can exacerbate pathology. Conversely, high CD200 expression on tumor cells or within the tumor microenvironment can promote immune evasion by dampening anti-tumor immunity. The axis is also a consideration in transplantation and infectious diseases.

Therapeutic implications involve strategies to modulate CD200R1 signaling. Agonists or CD200 mimetics aim to reduce inflammation in autoimmune or inflammatory diseases, while antagonists targeting the CD200-CD200R1 interaction are explored to enhance anti-tumor immune responses, with attention to balancing efficacy and risk of autoimmunity.